» Articles » PMID: 33544319

Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra

Overview
Publisher Current Science
Specialties Hematology
Oncology
Date 2021 Feb 5
PMID 33544319
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Post-transplant lymphoproliferative disorders are a rare and heterogeneous group of diseases, where large prospective studies have been difficult to perform and treatment paradigms are often based on retrospective studies. Here, we critically analyze and present the clinical algorithms commonly used for this disease, with a special focus on the challenges and differences of the approaches in the adult and pediatric populations.

Recent Findings: Clinical trials exploring combinations of immunochemotherapies with a sequential and risk-stratified strategy have demonstrated exciting results, but are hampered from specialty and age-determined silos. Approaches introducing novel-targeted therapies and cellular therapies are currently being explored with a goal of joining efforts across the pediatric and adult age spectra. We propose that future therapeutic approaches would benefit from combining pediatric and adult PTLD efforts, gaining from the experience garnered from the age- and subtype-specific tailored strategies, with the aim of limiting treatment-related toxicities while maximizing the efficacy. Joining of efforts holds enormous potential for accelerating access to novel therapeutic strategies for PTLD in the near future.

Citing Articles

Navigating Epstein-Barr Virus (EBV) and Post-Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Liver Transplantation: Current Knowledge and Strategies for Treatment and Surveillance.

Chen E, Dilwali N, Mysore K, Hassan S, Smith S, Karnsakul W Viruses. 2025; 17(2).

PMID: 40007011 PMC: 11861731. DOI: 10.3390/v17020254.


Pediatric Kidney Transplantation: Cancer and Cancer Risk.

Order K, Rodig N Semin Nephrol. 2024; 44(1):151501.

PMID: 38580568 PMC: 11734768. DOI: 10.1016/j.semnephrol.2024.151501.


Non-Hodgkin lymphoma in a kidney transplanted patient with methylmalonic acidemia: Metabolic susceptibility and the role of immunosuppression.

Burlina A, Burlina A, Mignani R, Cazzorla C, Gueraldi D, Puma A JIMD Rep. 2024; 65(2):56-62.

PMID: 38444575 PMC: 10910225. DOI: 10.1002/jmd2.12411.


Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.

Markouli M, Ullah F, Omar N, Apostolopoulou A, Dhillon P, Diamantopoulos P Cancers (Basel). 2022; 14(23).

PMID: 36497432 PMC: 9740763. DOI: 10.3390/cancers14235949.


Non-Hodgkin lymphoma after pediatric kidney transplantation.

Grenda R Pediatr Nephrol. 2021; 37(8):1759-1773.

PMID: 34633534 PMC: 9239945. DOI: 10.1007/s00467-021-05205-6.


References
1.
Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G . A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2013; 53(5):669-79. DOI: 10.3109/0284186X.2013.844853. View

2.
Zimmermann H, Trappe R . EBV and posttransplantation lymphoproliferative disease: what to do?. Hematology Am Soc Hematol Educ Program. 2013; 2013:95-102. DOI: 10.1182/asheducation-2013.1.95. View

3.
Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P . Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2019; 130(2):733-747. PMC: 6994129. DOI: 10.1172/JCI121127. View

4.
OReilly R, Lacerda J, Lucas K, Rosenfield N, Small T, Papadopoulos E . Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. Important Adv Oncol. 1996; :149-66. View

5.
Orjuela M, Gross T, Cheung Y, Alobeid B, Morris E, Cairo M . A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003; 9(10 Pt 2):3945S-52S. View